Outlook Therapeutics (OTLK) Change in Cash (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Change in Cash of -$929198.0 for Q1 2026, down 150.13% year-over-year from $1.9 million in Q1 2025, and down 256.34% quarter-over-quarter from $594339.0 in Q4 2025.
Outlook Therapeutics (OTLK) Change in Cash (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Change in Cash for 12 consecutive years, with -$929198.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash fell 150.13% year-over-year to -$929198.0; the TTM figure through Mar 2026 stood at $191913.0 (up 100.48% YoY), while the FY2025 annual figure was -$6.8 million, up 19.14% from the prior year.
- Change in Cash retreated to -$929198.0 in Q1 2026 per OTLK's latest filing, from $594339.0 in the prior quarter.
- Across five years, Change in Cash topped out at $36.9 million in Q1 2024 and bottomed at -$32.4 million in Q2 2022.
- Historically, Change in Cash has averaged -$3.7 million across 5 years, with a median of -$8.7 million in 2023.
- Annual changes were most pronounced in 2024 — Change in Cash jumped 523.25% — and 2026, when it tumbled 150.13%.
- Outlook Therapeutics' Change in Cash stood at $34.9 million in 2022, then tumbled by 137.3% to -$13.0 million in 2023, then increased by 29.23% to -$9.2 million in 2024, then surged by 106.44% to $594339.0 in 2025, then tumbled by 256.34% to -$929198.0 in 2026.
- Business Quant data shows OTLK's Change in Cash at -$929198.0 in Q1 2026, $594339.0 in Q4 2025, and -$817729.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -929,198.00 |
| Dec 31, 2025 | 594,339.00 |
| Sep 30, 2025 | -817,729.00 |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | -9.22 Mn |
| Sep 30, 2024 | -17.10 Mn |
| Jun 30, 2024 | -15.20 Mn |
| Mar 31, 2024 | 36.87 Mn |
| Dec 31, 2023 | -13.04 Mn |
| Sep 30, 2023 | -10.32 Mn |
| Jun 30, 2023 | -9.92 Mn |
| Mar 31, 2023 | -8.71 Mn |
| Dec 31, 2022 | 34.94 Mn |
| Sep 30, 2022 | -8.62 Mn |
| Jun 30, 2022 | -32.40 Mn |
| Mar 31, 2022 | -11.73 Mn |
| Dec 31, 2021 | 55.67 Mn |
| Sep 30, 2021 | -5.21 Mn |
| Jun 30, 2021 | -17.48 Mn |